HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Margaglione, M. PubMed PubMed Citation Articles by Margaglione, M.

The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype

¹ Genetica Medica, Università di Foggia
² Unità di Emostasi e Trombosi, I.R.C.C.S. "Casa Sollievo della Sofferenza", S. Giovanni Rotondo
³ Divisione di Ematologia, "S. Bortolo" Hospital, Vicenza
⁴ Centro Regionale Riferimento Coagulopatie Congenite, Azienda Ospedaliero-Universitaria Careggi, Firenze
⁵ Hemophilia and Thrombosis Center, "San Giovanni Bosco" Hospital, Napoli
⁶ "Angelo Bianchi Bonomi" Hemophilia and Thrombosis Center, University of Milan and IRCCS Maggiore Hospital, Mangiagalli and Regina Elena Foundation, Milan
⁷ Servizio Trasfusionale, Castelfranco Veneto Hospital (TV), ASL 8 Regione Veneto, Castelfranco Veneto
⁸ Regional Reference for Inherited Bleeding Disorders, University Hospital of Parma
⁹ Dipartimento di Scienze Mediche e Chirurgiche, Università di Padova
¹⁰ Laboratorio di Ematologia ed Emofilia, IV Divisione di Pediatria, Istituto Gaslini, Genova
¹¹ Dipartimento di Biochimica e Biotecnologie Mediche, Università di Napoli "Federico II", CEINGE Biotecnologie Avanzate, Napoli
¹² SOD Diagnostica Genetica, Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy

Correspondence: Maurizio Margaglione, MD, Cattedra di Genetica Medica, Dipartimento di Scienze Biomediche, Università degli Studi di Foggia, viale Pinto, 71100 Foggia, Italy. E-mail: m.margaglione{at}unifg.it

Background: The high mutational heterogeneity of hemophilia A is a challenge for the provision of genetic services. We plan to identify the mutation in patients with hemophilia A in order to create a confidential national database of mutations for the optimization of genetic services in Italy.

Design and Methods: The factor VIII gene (F8) was analyzed in 1296 unrelated patients with hemophilia A using screening methods for intron 22 and 1 inversions and rare mutations (denaturing high performance liquid chromatography, conformation sensitive gel electrophoresis) and/or direct sequencing.

Results: F8 mutations were identified in 874 (89%), 146 (89%), and 133 (94%) families with severe, moderate, or mild hemophilia A, respectively. Mutations predicting a null allele were responsible for 80%, 15%, and less than 1% of cases of severe, moderate, or mild hemophilia A, respectively. About 40% of missense and nonsense mutations occurred at a CpG site, arginines being most frequently affected. Of the small deletions or insertions, 29% occurred at one of two stretches of adenines, codons 1191–1194 (8As) and 1439–1441 (9As). Overall, these "hotspots" accounted for 31% of the point mutations in the patients with hemophilia A. Inhibitors developed in 22% of the patients with severe hemophilia A, 8% of those with moderate disease and in 4% of patients with mild hemophilia A. Patients who had severe hemophilia A and mutations predicting a null allele developed inhibitors more frequently (22 to 67%) than patients with missense mutations (5%).

Conclusions: We report a wide spectrum of mutations in a large national database. The type of mutation was a strong predictor of the clinical phenotype. This database is expected to considerably improve the genetic counselling and medical care of families with hemophilia A in Italy.

Key words: hemophilia A, F8 gene, mutations, hotspots, phenotype.